Flow cytometric immunophenotyping of hematological malignancies: the way forward in Nigeria

John Ayodele OlaniyiDepartment of Hematology, University College Hospital, Ibadan, NigeriaAim: This review serves to awaken the interest of stakeholders involved in research and management of hematological malignancies (HM) in the efficacy of flow cytometry in the immunophenotypic characterization o...

Full description

Bibliographic Details
Main Author: Olaniyi JA
Format: Article
Language:English
Published: Dove Medical Press 2011-07-01
Series:Pathology and Laboratory Medicine International
Online Access:http://www.dovepress.com/flow-cytometric-immunophenotyping-of-hematological-malignancies-the-wa-a7788
id doaj-7491c294d6454d67b37f04a220003c3e
record_format Article
spelling doaj-7491c294d6454d67b37f04a220003c3e2020-11-24T21:49:49ZengDove Medical PressPathology and Laboratory Medicine International1179-26982011-07-012011default1724Flow cytometric immunophenotyping of hematological malignancies: the way forward in NigeriaOlaniyi JAJohn Ayodele OlaniyiDepartment of Hematology, University College Hospital, Ibadan, NigeriaAim: This review serves to awaken the interest of stakeholders involved in research and management of hematological malignancies (HM) in the efficacy of flow cytometry in the immunophenotypic characterization of leukemias and lymphomas. This well-defined characterization plays a crucial role in diagnosis, classification, prognostic evaluation, and detection of minimal residual disease, in the context of clinical features and morphological diagnosis.Methodology: Relevant literature was retrieved to highlight the principles of operation of flow cytometry, indications and applications, derivable clinical information and clinical relevance, sources of error, and necessary steps towards definitive and specific diagnosis of each HM.Conclusion: Flow cytometric immunophenotyping (FCIMPT) of HM is highly demanding and capital intensive but its usefulness in profiling these exceptionally heterogeneous disorders, and allowing proper classification along the latest WHO classification guidelines, thereby paving the way for targeted therapy and clinical trial-driven management, significantly outweighs the cost, which can be fully recovered if properly managed. In a low-resource setting like Nigeria, limited immunohistochemistry serves to bridge the gap in technological advancement.Keywords: flow cytometry, immunophenotyping, hematological malignancies, Nigeriahttp://www.dovepress.com/flow-cytometric-immunophenotyping-of-hematological-malignancies-the-wa-a7788
collection DOAJ
language English
format Article
sources DOAJ
author Olaniyi JA
spellingShingle Olaniyi JA
Flow cytometric immunophenotyping of hematological malignancies: the way forward in Nigeria
Pathology and Laboratory Medicine International
author_facet Olaniyi JA
author_sort Olaniyi JA
title Flow cytometric immunophenotyping of hematological malignancies: the way forward in Nigeria
title_short Flow cytometric immunophenotyping of hematological malignancies: the way forward in Nigeria
title_full Flow cytometric immunophenotyping of hematological malignancies: the way forward in Nigeria
title_fullStr Flow cytometric immunophenotyping of hematological malignancies: the way forward in Nigeria
title_full_unstemmed Flow cytometric immunophenotyping of hematological malignancies: the way forward in Nigeria
title_sort flow cytometric immunophenotyping of hematological malignancies: the way forward in nigeria
publisher Dove Medical Press
series Pathology and Laboratory Medicine International
issn 1179-2698
publishDate 2011-07-01
description John Ayodele OlaniyiDepartment of Hematology, University College Hospital, Ibadan, NigeriaAim: This review serves to awaken the interest of stakeholders involved in research and management of hematological malignancies (HM) in the efficacy of flow cytometry in the immunophenotypic characterization of leukemias and lymphomas. This well-defined characterization plays a crucial role in diagnosis, classification, prognostic evaluation, and detection of minimal residual disease, in the context of clinical features and morphological diagnosis.Methodology: Relevant literature was retrieved to highlight the principles of operation of flow cytometry, indications and applications, derivable clinical information and clinical relevance, sources of error, and necessary steps towards definitive and specific diagnosis of each HM.Conclusion: Flow cytometric immunophenotyping (FCIMPT) of HM is highly demanding and capital intensive but its usefulness in profiling these exceptionally heterogeneous disorders, and allowing proper classification along the latest WHO classification guidelines, thereby paving the way for targeted therapy and clinical trial-driven management, significantly outweighs the cost, which can be fully recovered if properly managed. In a low-resource setting like Nigeria, limited immunohistochemistry serves to bridge the gap in technological advancement.Keywords: flow cytometry, immunophenotyping, hematological malignancies, Nigeria
url http://www.dovepress.com/flow-cytometric-immunophenotyping-of-hematological-malignancies-the-wa-a7788
work_keys_str_mv AT olaniyija flowcytometricimmunophenotypingofhematologicalmalignanciesthewayforwardinnigeria
_version_ 1725887232250740736